DB
Therapeutic Areas
Relay Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RLY-4008 (lirafugratinib) | FGFR2-altered solid tumors (e.g., cholangiocarcinoma) | Phase 1/2 |
| RLY-2608 | PI3Kα-mutant solid tumors (e.g., breast cancer) | Phase 1 |
| GDC-1971 (formerly RLY-1971) | SHP2 inhibition in solid tumors | Phase 1 |
| RLY-2139 | CDK2 inhibition in solid tumors | Preclinical |
| Undisclosed Program | Mutant RAS (KRAS G12C & beyond) | Discovery |
Leadership Team at Relay Therapeutics
SP
Sanjiv Patel, M.D.
President and Chief Executive Officer
BA
Brian Adams
Chief Legal Officer and Corporate Secretary
MH
Margaret Horn
Chief Financial Officer
KH
Keith Horn
Chief Operating Officer
SB
Sourav Bandyopadhyay, Ph.D.
Chief Scientific Officer
CR
Chris Roberts, Ph.D.
Chief Technology Officer
CS
Catherine Sabatos-Peyton, Ph.D.
Chief Business Officer
DB
David Berman, M.D., Ph.D.
Senior Vice President, Clinical Development
AB
Alexis Borisy
Chairman of the Board
CB
Cynthia Butitta
Board Member